IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2746-2752

  Ye, Xiao Lei ^a,c   Zhao, Ya Rong ^a,b   Weng, Guo Bin ^a   Chen, Yi Chen ^b   Wei, Xue Ni ^a,b   Shao, Jing Ping ^c   Ji, Hui ^b  

^a Yinzhou People's Hospital   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Ningbo Institute of Medical Sciences   (China)

Author keywords

Apoptosis; Gastric cancer; IL 33; Invasion

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; OXALIPLATIN; ST2 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GASTRIC CANCER CELL LINE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; INFLAMMATION; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTHRACENES; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION; INTERLEUKIN-33; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS;

EID: 84928910783     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3898     Document Type: Article

References (33)

1. Oguma K, Oshima H and Oshima M: Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncol 6: 515-526, 2010.
2. Ernst P: Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol Ther 13 (Suppl 1): S13-S18, 1999.
3. Fox JG and Wang TC: Inflammation, atrophy, and gastric cancer. J Clin Invest 117: 60-69, 2007.
4. Multhoff G, Molls M and Radons J: Chronic inflammation in cancer development. Front Immunol 2: 98, 2012.
5. Mosaffa F, Kalalinia F, Lage H, Afshari JT and Behravan J: Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem 363: 385-393, 2012.
6. Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, Pan WY, Chen HH, Cheng YH, Lee KD, Chen MF, et al: Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol 86: 872-887, 2013.
7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490, 2005.
8. + TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. Cytokine 59: 352-357, 2012.
9. Mohran ZY, Ali-Eldin FA and Abdel Aal HA: Serum interleukin-18: does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma? Arab J Gastroenterol 12: 29-33, 2011.
10. Tsuboi K, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Kato H and Kuwano H: Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 205: 207-214, 2004.
11. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A and Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 12: 4473-4477, 2006.
12. Smith DE: The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 89: 383-392, 2011.
13. Moussion C, Ortega N and Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3: e3331, 2008.
14. Sun P, Ben Q, Tu S, Dong W, Qi X and Wu Y: Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56: 3596-3601, 2011.
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
16. Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, Saito H, Matsushima K, Ohta K, Yamamoto K and Yamaguchi M: Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 88: 1245-1253, 2008.
17. Bianchetti L, Marini MA, Isgrò M, Bellini A, Schmidt M and Mattoli S: IL-33 promotes the migration and proliferation of circulating fibrocytes from patients with allergen-exacerbated asthma. Biochem Biophys Res Commun 426: 116-121, 2012.
18. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F and Orditura M: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 36 (Suppl 3): S11-S15, 2010.
19. Xu Y, Huang S, Liu ZG and Han J: Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J Biol Chem 281: 8788-8795, 2006.
20. Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang Z, Cui A, Hu X, Cui L, Yang Y and Liu CY: Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. Clin Immunol 154: 116-126, 2014.
21. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O and Radeke HH: High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 6: 311-318, 2013.
22. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S and Kastelein RA: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179: 2551-2555, 2007.
23. Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C and Pan H: p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett 344: 174-179, 2014.
24. Yuan L, Wang J, Xiao H, Wu W, Wang Y and Liu X: MAPK signaling pathways regulate mitochondrial-mediated apoptosis induced by isoorientin in human hepatoblastoma cancer cells. Food Chem Toxicol 53: 62-68, 2013.
25. Fan M and Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 4: 253-267, 2001.
26. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
27. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000.
28. Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, Choi HY, Jeong MY and Cho SG: Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta 1763: 958-968, 2006.
29. Kim J, Kim C, Kim TS, Bang SI, Yang Y, Park H and Cho D: IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 344: 1284-1289, 2006.
30. Luan L, Zhao Y, Xu Z, Jiang G, Zhang X, Fan C, Liu D, Zhao H, Xu K, Wang M, et al: Diversin increases the proliferation and invasion ability of non-small-cell lung cancer cells via JNK pathway. Cancer Lett 344: 232-238, 2014.
31. Fontana VA, Sanchez M, Cebral E and Calvo JC: Interleukin-1 beta regulates metalloproteinase activity and leptin secretion in a cytotrophoblast model. Biocell 34: 37-43, 2010.
32. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC and Lin YS: The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 231: 180-189, 2013.
33. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN and Lukic ML: Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 134: 1669-1682, 2014.